|Bid||5.36 x 800|
|Ask||5.37 x 800|
|Day's Range||5.31 - 5.48|
|52 Week Range||5.27 - 30.13|
|Beta (3Y Monthly)||2.07|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Adamas (ADMS) delivered earnings and revenue surprises of 4.42% and -8.75%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Emeryville, California-based company said it had a loss of $1.08. The results surpassed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...
Adamas (ADMS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Anyone researching Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) might want to consider the historical volatility of the share price. Volatility is considered to be a measure of risk in modern finance theory. Investors may think of vo...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on March 4) Abbott Laboratories (NYSE: ABT ) Ascendis Pharma A/S ...
DENTSPLY SIRONA's (XRAY) overall growth strategy depends on product innovation and R&D focus, which is likely to drive the top line in Q4.
Adamas (ADMS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AptarGroup (ATR) fourth-quarter results will benefit from successful product roll outs and focus on improving operations despite input cost inflation and customer plant shutdowns.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! We've lost count of how many timesRead More...
Molina Healthcare (MOH) is expected to gain in Q4 on the back of membership strength and its streamlining initiative. However, the same might be partly offset by a dismal Marketplace business.
A volatile stock market dished out an extra dose of punishment to riskier assets, including these three small-cap pharma companies.
Here's a roundup of top developments in the biotech space over the last 24 hours. No biotech stocks hit 52-week highs Tuesday. Down In The Dumps (Biotech stocks hitting 52-week lows on Dec. 18) Accelerate ...
Insider Monkey has processed numerous 13F filings of hedge funds and famous investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds and investors’ positions as of the end of the third quarter. You can find write-ups about an individual hedge fund’s trades on numerous financial news websites. […]
The Emeryville, California-based company said it had a loss of $1.22 per share. The results beat Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was ...